Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES | 23 | 17 | -0,26 % | ||
| AMGEN | 8 | 27 | -0,07 % | ||
| BIONTECH | 5 | 13 | +0,13 % | ||
| BIOGEN | 3 | 54 | -0,20 % | ||
| IDEAYA BIOSCIENCES | 3 | 3 | -1,41 % | ||
| BIOCRYST PHARMACEUTICALS | 3 | - | +1,43 % | ||
| DENALI THERAPEUTICS | 3 | - | -2,18 % | ||
| QUANTUM-SI | 3 | - | -1,40 % | ||
| SUMMIT THERAPEUTICS | 2 | 12 | -2,30 % | ||
| GILEAD SCIENCES | 2 | 5 | -0,45 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21:06 | Oppenheimer raises Neurocrine Biosciences price target on acquisition | 2 | Investing.com | ||
| 20:58 | Oppenheimer hebt Kursziel für Neurocrine Biosciences nach Akquisition an | - | Investing.com Deutsch | ||
| 20:34 | Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval | 3 | Zacks | ||
| 20:26 | Takeda tears up Denali partnership, returning dementia asset amid restructuring | 4 | FierceBiotech | ||
| 20:18 | Baird reiterates Neurocrine Bio stock rating on acquisition potential | 1 | Investing.com | ||
| 20:10 | Baird bestätigt NBIX-Rating: Akquisition von Soleno birgt Blockbuster-Potenzial | 1 | Investing.com Deutsch | ||
| 19:46 | William Blair bestätigt "Outperform"-Rating für Amgen nach positiven Tepezza-Studiendaten | 3 | Investing.com Deutsch | ||
| 19:42 | William Blair reiterates Amgen stock rating on positive Tepezza data | 3 | Investing.com | ||
| 19:30 | Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why | 3 | Benzinga.com | ||
| 19:26 | Biontech-Gründer Türeci und Sahin: Top-Investoren umwerben neues Projekt - ohne es zu kennen | 28 | Der Tagesspiegel | ||
| 18:34 | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | 2 | Zacks | ||
| 17:46 | FDA floats new clinical trial reforms; Takeda punts Denali brain drug | 6 | BioPharma Dive | ||
| 17:18 | FDA Flags Anktiva Claims While ImmunityBio Pushes Regulatory Fixes | 17 | Benzinga.com | ||
| 17:18 | Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder | 1 | Benzinga.com | ||
| 17:10 | Neurocrine, eying 'blockbuster in the making,' strikes its largest-ever M&A deal with $2.9B Soleno buyout | 3 | FiercePharma | ||
| 17:06 | Amgen Posts 77% Response In Thyroid Eye Disease Study | 3 | Benzinga.com | ||
| 16:50 | Eilmeldung am Abend: BIONTECH SE ADR vor neuem Impuls? | 13 | Maximilian Berger | ||
| 16:48 | Amgen posts positive late-stage results for subcutaneous Tepezza | 4 | Seeking Alpha | ||
| 16:46 | UBS bestätigt Kaufempfehlung für Neurocrine Bio nach Übernahmemeldung | 2 | Investing.com Deutsch | ||
| 16:46 | Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout | 1 | BioPharma Dive |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.